![]()
Hyperscience, a market leader in enterprise AI infrastructure software, focused on Intelligent Document Processing (IDP), today announced that MiraVista Diagnostics, a specialty fungal diagnostic laboratory, has selected Hyperscience to modernize and automate its document intake operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118558854/en/
Headquartered in Indianapolis, Indiana, MiraVista Diagnostics is a specialty reference laboratory focused on the diagnosis of serious fungal infections. The laboratory serves hospitals, health systems, reference laboratories, veterinary practices, and research institutions across the United States and internationally. Its CAP-accredited, CLIA-certified laboratory, which also holds a New York State clinical laboratory permit, provides specialized high-complexity antigen, antibody, and molecular testing.
As customer demand for MiraVista’s testing services continued to increase, the organization embarked on an initiative to modernize the laboratory requisition intake process. By automating the classification and extraction of information from incoming laboratory requisitions, Hyperscience will enable MiraVista to deliver trusted, structured data directly into its laboratory information management system. The integration is designed to reduce manual data entry, improve operational efficiency, and streamline the flow of information across critical diagnostic workflows.
“Efficient intake is foundational to delivering the level of service our healthcare partners expect. When test requests and supporting documentation are processed accurately and without delay, we can provide timely diagnostic information to support patient care,” said John Witt, Senior Clinical Services Manager at MiraVista Diagnostics. “Modernizing our pre-analytic operations helps us improve consistency, increase efficiency, and strengthen our ability to respond to the needs of the clinicians, veterinarians, and organizations that depend on our services.”
The decision followed a focused evaluation in which Hyperscience worked closely with MiraVista Diagnostics to understand its operational challenges and develop a solution aligned with its business objectives. Hyperscience partnered with MiraVista Diagnostics to establish success criteria and demonstrate its native AI document understanding capabilities against representative laboratory requisitions, validating an approach designed for accurate, low-latency processing.
This hands-on engagement enabled the teams to move quickly from initial evaluation to a working proof of concept, with a tailored, low-latency solution designed to meet MiraVista’s operational requirements and support a streamlined implementation.
“In healthcare, the speed and accuracy of information can have a direct impact on operational efficiency and the delivery of patient care,” said Andrew Joiner, CEO of Hyperscience. “MiraVista Diagnostics recognizes that transforming complex laboratory documents into trusted, actionable data is essential to modernizing diagnostic workflows. By automating laboratory requisition processing, we’re helping MiraVista reduce manual bottlenecks, accelerate operations, and enable its teams to focus on the critical work of delivering timely, high-quality diagnostic services.”
The engagement represents an important application of intelligent document processing within clinical laboratory operations, demonstrating how organizations can modernize document-intensive workflows while improving operational efficiency and responsiveness. By reducing reliance on manual data entry through a scalable automated intake process, MiraVista Diagnostics is better positioned to manage incoming requests efficiently and support the evolving needs of its healthcare partners.
About MiraVista Diagnostics
MiraVista Diagnostics is a family-owned specialty diagnostic laboratory and IVD manufacturer focused on the detection and diagnosis of serious fungal infections in humans and animals. The company was founded in 2002 by infectious disease physician Dr. L. Joseph Wheat, who developed the first Histoplasma antigen test in the 1980s. Headquartered in Indianapolis, Indiana, MiraVista operates a CAP-accredited, CLIA-certified laboratory and offers antigen, antibody, and molecular testing for Histoplasma, Blastomyces, Coccidioides, and other fungal pathogens. Its scientists, laboratory specialists, and clinical advisors work directly with hospitals, health systems, reference laboratories, and veterinarians on difficult diagnostic cases. MiraVista’s mission is to advance diagnostic solutions to save lives. For more information, visit www.miravistalabs.com.
About Hyperscience
Hyperscience is a market leader in enterprise AI infrastructure software, focused on Intelligent Document Processing (IDP). The Hyperscience Hypercell platform unlocks the value of an organization’s unstructured data through the automation of end-to-end processes, and transforms complex documents and unstructured content into trusted enterprise data that powers workflows, applications, copilots and autonomous agents. This enables organizations to transform manual, siloed processes into a strategic advantage, resulting in a faster path to decisions, actions, and revenue; positive and engaging customer, public, and patient experiences; and dramatic increases in productivity.
Hyperscience delivers measurable enterprise impact through higher automation, greater accuracy, and increased operational efficiency. The IDC Business Value Study found organizations using Hyperscience achieved 615% three-year ROI, $8.6M in average annual benefits, and payback in approximately seven months.
Leading organizations across the globe rely on Hyperscience to drive their hyperautomation initiatives, including Charles Schwab, HM Revenue and Customs, Rula, Stryker, Tokio Marine, The United States Social Security Administration, The United States Department of Veterans Affairs, and U.S. Citizenship and Immigration Services. The company is funded by top tier investors including Bessemer Venture Partners, Battery, FirstMark, Stripes, and Tiger Global.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261118558854/en/
Media gallery